Patient self-report tool on side effects in cancer clinical trials validated by landmark study

the ONA take:

A landmark study has validated the National Cancer Institute’s Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) as an accurate, reliable, and responsive measure of side effects experienced by patients participating in clinical trials. This study compared the PRO-CTCAE with other patient-reported and clinical measures.

More than 1,000 patients from clinical practices across the United States, including seven cancer centers, were recruited to participate in the study.

They were asked to complete the PRO-CTCAE before appointments. Their reports were compared against other established measures of symptoms such as case and quality of life reports and prescription information.

The researchers validated 119 of 125 PRO-CTCAE questions against the established measurement tools usually based on information from providers. Underrepresentation in the study population prohibited evaluation of the five questions that could not be validated.

This study was unique in that more than 100 distinct questions about symptomatic adverse events were validated simultaneously.

Patient self-report tool on side effects in cancer clinical trials is validated by landmark study
The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is accurate, reliable.
A multicenter study involving Mayo Clinic researchers has found that the National Cancer Institute's Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), was accurate, reliable and responsive, compared to other, established patient-reported and clinical measures. The study is published today in the journal JAMA Oncology.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs